Abstract:Muhammad Asad Faruqi, 1 Malik M Khurram S Khan, 1 David M Mannino 1, 2 1 University of Kentucky College of Medicine, Lexington, KY, USA; 2 COPD Foundation, Miami, FL, USA Correspondence: David M Mannino, Department of Medicine, University of Kentucky College of Medicine, 800 Rose Street, Lexington, KY, 40536, USA, Email Ensifentrine is a novel inhalational phosphodiesterase (PDE)3 and PDE4 inhibitor which improves bronchodilation and decreases inflammatory markers by acting locally on the bronchial tissue, with minimal systemic effects. Both preclinical and clinical trials have demonstrated benefits of this therapy, including improvement in lung function and reduction in exacerbations. This therapy is currently under review by the US Food and Drug Administration with a decision expected in 2024. Keywords: chronic obstructive pulmonary disease, therapy, phosphodiesterase inhibitor Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory disorder of the respiratory system which is characterized by irreversible airflow obstruction, remodeling of the airways and acute exacerbations leading to lung function decline, progressive dyspnea, and cough. 1 Treatment of COPD is aimed towards reducing symptoms like shortness of breath and mucous production, preventing flare-ups, slowing disease progression and improving survival. COPD therapies involve both non-pharmacological and pharmacological interventions. Some patients on maximal therapies, including inhaled bronchodilators and steroids and oral phosphodiesterase 4 (PDE4) inhibitors, can still be symptomatic. Thus, new therapies are needed that can improve lung function and airway inflammation when used in addition to existing therapies. 2,3 In addition, current inhaled therapies may not be tolerated by all patients. Thus, therapies with alternative mechanisms of action are needed. In this article, we review the literature available on ensifentrine, a novel phosphodiesterase inhibitor that has the potential to be an add-on therapy for patients with COPD. Ensifentrine (RPL554) is a novel drug that works by dual inhibition of phosphodiesterase (PDE) 3 and 4 enzymes (PDE3, PDE4) and is designed to be delivered via inhalation. 4 Inhibitors of PDE3 and PDE4 target multiple respiratory functions at the cellular and tissue level (Figure 1). PDE3 regulates cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) levels in the airway smooth muscles, which mediates bronchial tone. 5 PDE4 regulates cAMP levels in the airway cells associated with inflammation and is involved in activation of these cells. 6 PDE4 inhibitors can also activate the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and improve bronchial epithelial cell ciliary movements. 7 Evidence has recently emerged that dual inhibition of PDE3 and PDE4 enzymes results in a synergistic effect of decreased inflammation and improved bronchodilation as both iso-forms of PDE are expressed in the inflammatory cells and airway smooth muscles. 8,9 This article explores the evidence to date regarding ensifentrine as a novel therapeutic option for the treatment of COPD. Figure 1 Combined inhibition of phosphodiesterase (PDE) 3 and PDE4 has additive and synergistic anti-inflammatory and bronchodilatory effects versus inhibition of either PDE3 or PDE4 alone. Furthermore, it increases mucociliary clearance. In red, the main PDE involved in the activity of the specific cell. With permission, from Current Opinion in Pharmacology. Notes : Reprinted from Current Opinion in Pharmacology, Volume 56, Matera MG, Cazzola M, Page C, Prospects for COPD treatment. pages 74–84, copyright 2021, with permission from Elsevier. 3 Several in vitro and in vivo studies evaluated the effect of PDE3/4 inhibitors on airway smooth muscles and degree of inflammation. One study investigated the effects of ensifentrine (RPL554) on the tone of isolated human airway smooth muscles and its synergistic actions when used in conjunction with other bronchodilators including muscarinic antagonists and beta-adrenergic agonists. The study demonstrated that ensifentrine caused relaxation of the bronchial smooth muscles and had a synergistic effect when used with muscarinic antagonists. 10 Ensifentrine's effect on bronchial epithelial cell cultures obtained from normal and Cystic Fibrosis (CF) patients with F508del genotype has also been evaluated. 11 It stimulates CFTR-dependent chloride ion secretion across bronchial epithelial cells and increases cilia beat frequency in primary human bronchial epithelial cells. It also decreases the production of monocyte chemoattractant protein-1 and granulocyte monocyte colony -Abstract Truncated-

Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone

The Effects of Rolipram on PDE Activity and IL-4 Level in the Lung Tissue of Ovalbumin Sensitized and Repeatedly Challenged Rats

Inhibition of acetamide-45 on airway smooth muscle contraction induced by electric field stimulation and methacholine in vitro]

Effects of the Selective Muscarinic Receptor Antagonist Penehyclidine Hydrochloride on the Respiratory Tract.

Blockade Of Ltc4 Synthesis Caused By Additive Inhibition Of Giv-Pla(2) Phosphorylation: Effect Of Salmeterol And Pde4 Inhibition In Human Eosinophils

Effects of Phosphodiesterase 4 Inhibitor on Cough Response in Guinea Pigs Sensitized and Challenged with Ovalbumin

PGE 2 Desensitizes Β -Agonist Effect on Human Lung Fibroblast-Mediated Collagen Gel Contraction Through Upregulating PDE4.

Role of M2 Receptor on the Muscarinic Functional Antagonism in the Human Isolated Bronchus

Imidazobenzodiazepine PI320 Relaxes Mouse Peripheral Airways by Inhibiting Calcium Mobilization

Characterization Of A Long Acting Smooth Muscle Myosin Inhibitor, Ck-2125927, As A Novel Therapeutic Mechanism For Bronchodilation

Phosphodiesterase 4 Inhibitors Attenuate the Asthma Phenotype Produced by β2-Adrenoceptor Agonists in Phenylethanolamine N-Methyltransferase-Knockout Mice

[Effects of Phosphodiesterase-4 Inhibitor on the Mucin Secretion in Airway Stimulated with Acrolein: Experiment with Rats].

Heat Shock-Related Protein 20 Peptide Decreases Human Airway Constriction Downstream of β2-Adrenergic Receptor

Effects of Selective Phosphodiesterase 4 Inhibitor on Expression of Aquaporin 5 in Airway Mucus Hypersecretion Model of Rats

New promising agents against COPD and asthma among the amides of 1-oxo-3-phenyl-isochroman-6-carboxylic acid

Fenoterol functionally activates the β₃-adrenoceptor in human urinary bladder, comparison with rat and mouse: implications for drug discovery

Pharmacology of the single isomer, esuberaprost (beraprost-314d) on pulmonary vascular tone, IP receptors and human smooth muscle proliferation in pulmonary hypertension

A PI3Kγ Mimetic Peptide Triggers CFTR Gating, Bronchodilation, and Reduced Inflammation in Obstructive Airway Diseases

[Effect of Triptolide on Airway Remodeling and the Expression of Phosphoinositide 3-Kinases in Asthmatic Rats].

Perspectives on Ensifentrine and Its Therapeutic Potential in the Treatment of COPD: Evidence to Date

Effects of (a Combination of) the Beta2-Adrenoceptor Agonist Indacaterol and the Muscarinic Receptor Antagonist Glycopyrrolate on Intrapulmonary Airway Constriction